Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGJ398 plus BYL719 in advanced solid tumors with PIK3CA mutation
NL-OMON40550Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of infigratinib and alpelisib in Nonhematologic neoplasms, sponsored by Novartis. Primary endpoint: Maximum tolerated dose and/or recommended dose for expansion. Started Oct 2013; status: active, not recruiting.
02
Drugs
infigratinibalpelisib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON40550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40550.